Mengqi Guo

Dr. Mengqi Guo


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
MGMengqi Guo
Mengqi Guo
JZJinyu Zheng
Jinyu Zheng
WXWei-Hui Xie
Wei-Hui Xie
BCBing-Hua Chen
Bing-Hua Chen
DADongaolei An
Dongaolei An
LWLianming Wu
Lianming Wu
Background/Objectives: To explore the predictive value of pericardial fat tissue (PFT) radiomics for left ventricular (LV) involvement and major adverse cardiac events (MACE) in arrhythmogenic right ventricular cardiomyopathy (ARVC). Methods: In this retrospective multicenter study, LV involvement was assessed using cardiac magnetic resonance (CMR). A radiomic score (RS) derived from PFT was developed to predict LV involvement. The predictive accuracy of the RS was evaluated through receiver operating characteristic (ROC) analysis. Additionally, multivariable Cox regression analysis was employed to assess the prognosis across the entire dataset. Kaplan–Meier survival curves were used to evaluate the association between RS and MACE. Results: A total of 122 patients (mean age, 44 years ± 17; 76 male) were included, 90 for a development set and 32 for an external test set. The RS demonstrated good predictive performance for LV involvement in both the development and external test sets, with area under the curve (AUC) values of 0.771 and 0.785, respectively. Moreover, a high RS (≥−0.38) was independently associated with MACE during a median follow-up of 5 years (hazard ratio, 3.452; p < 0.001). Based on the right ventricular ejection fraction (RVEF) and RS, a simplified risk score was developed to categorize patients into three groups: high-risk (RVEF ≤ 40%, RS ≥ −0.38), intermediate-risk (RVEF ≤ 40%, RS < −0.38 or RVEF > 40%, RS ≥ −0.38), and low-risk (RVEF > 40%, RS < −0.38). Conclusions: The PFT radiomics can predict LV involvement and be associated with MACE in ARVC patients.